Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

Phase 2
Conditions
Lymphoma
First Posted Date
2011-03-03
Last Posted Date
2014-01-10
Lead Sponsor
Auxilio Mutuo Cancer Center
Target Recruit Count
70
Registration Number
NCT01307592
Locations
🇵🇷

Centro de Cancer del Hospital Auxilio Mutuo, San Juan, Puerto Rico

Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma

Phase 2
Terminated
Conditions
Lymphoma
Interventions
Biological: Rituximab
Drug: lenalidomide
First Posted Date
2011-03-03
Last Posted Date
2023-06-27
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
154
Registration Number
NCT01307605
Locations
🇸🇪

University Hospital of Linkoping, Linkoping, Sweden

🇸🇪

Karolinska University Hospital - Huddinge, Stockholm, Sweden

🇸🇪

Sunderbyn Hospital, Lulea, Sweden

and more 30 locations

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

First Posted Date
2011-02-25
Last Posted Date
2019-01-08
Lead Sponsor
Sherif S. Farag
Target Recruit Count
14
Registration Number
NCT01303965
Locations
🇺🇸

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

Phase 2
Completed
Conditions
Acute Myeloid Leukemia
Interventions
Drug: azacitidine
Drug: Lenalidomide
First Posted Date
2011-02-23
Last Posted Date
2016-03-16
Lead Sponsor
French Innovative Leukemia Organisation
Target Recruit Count
120
Registration Number
NCT01301820
Locations
🇫🇷

Mathilde HUNAULT BERGER, Angers, France

Lenalidomide in Kaposi Disease Associated With HIV Infection

Phase 2
Terminated
Conditions
HIV Infection Associated Kaposi Disease
Interventions
Drug: Lenalidomide
First Posted Date
2011-01-24
Last Posted Date
2014-08-01
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
12
Registration Number
NCT01282047
Locations
🇫🇷

Valerie Martinez, Clamart, France

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

Phase 2
Completed
Conditions
Adult T Cell Leukemia/Lymphoma
Interventions
Drug: Lenalidomide
First Posted Date
2011-01-11
Last Posted Date
2016-05-23
Lead Sponsor
Columbia University
Target Recruit Count
4
Registration Number
NCT01274533
Locations
🇺🇸

Columbia University Medical Center, New York, New York, United States

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

First Posted Date
2011-01-06
Last Posted Date
2015-06-04
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT01271283
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Lenalidomide
First Posted Date
2010-12-21
Last Posted Date
2023-05-26
Lead Sponsor
Fondazione EMN Italy Onlus
Target Recruit Count
53
Registration Number
NCT01264315
Locations
🇮🇹

A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer

First Posted Date
2010-12-06
Last Posted Date
2020-03-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
24
Registration Number
NCT01254617
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

First Posted Date
2010-12-06
Last Posted Date
2017-09-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
17
Registration Number
NCT01254578
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy